NG-350A-02 NG-350A-02: A multicentre, open-label, non-randomized, phase 1a/1b study of NG-350A, a tumour-selective anti-CD40-expressing adenoviral vector, in combination with pembrolizumab in patients with metastatic or advanced epithelial tumours (FORTIF

NCT05165433

NG-350A-02: A multicentre, open-label, non-randomized, phase 1a/1b study of NG-350A, a tumour-selective anti-CD40-expressing adenoviral vector, in combination with pembrolizumab in patients with metastatic or advanced epithelial tumours (FORTIFY)

Associated Conditions

Multiple Tumor Types

Principal Investigator

Guru Sonpavde

Sponsor

Akamis Bio

The purpose of this research study is to test how safe and well-tolerated treatment with the study drug is in combination with pembrolizumab and to find out more about the side-effects. The study aims to determine the following: What effects, good and/or bad, the study drug in combination with pembrolizumab have on you and your cancer disease. How your body responds to the study drug in combination with pembrolizumab. To find out more about what happens to study drug in the body after administration.

This study is currently enrolling.